文献速递核素与放射性配体治疗肿瘤 PET/CT

90Y微球SIRT治疗伴门静脉癌栓HCC:99mTc-MAA SPECT/CT剂量学的高临床影响

90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry.
PubMed 文献 · Semin Nucl Med · 2019-02-07

本文综述了基于99mTc-MAA SPECT/CT的预测剂量学在伴门静脉癌栓(PVT)肝细胞癌(HCC)患者90Y微球选择性内放射治疗(SIRT)中的应用。报告了树脂微球肿瘤剂量阈值100–120 Gy、玻璃微球205–257 Gy可获缓解,并首次提出「剂量学血管造影」概念。良好PVT候选者(肿瘤吸收剂量≥205 Gy且PVT靶向良好)中位总生存20.2个月,差候选者仅3个月,12%患者降期后切除。

要点

  • MAA SPECT/CT预测剂量学可用于90Y微球SIRT前个体化剂量评估。
  • 树脂微球肿瘤剂量100–120 Gy、玻璃微球205–257 Gy为报告的反应阈值。
  • 玻璃微球治疗良好PVT候选者中位OS 20.2个月,差候选者仅3个月。

核心结论

  • 基于MAA剂量学的个体化剂量方法现已可用于90Y树脂或玻璃微球,并具有特定终点。
  • 在PVT患者中个体化剂量学的临床影响尤其高,良好候选者中位总生存达20.2个月而差候选者仅3个月。

研究设计与样本

  • 本文为综述,概述基于99mTc-MAA定量闪烁扫描(SPECT/CT)的预测剂量学概念。
  • 讨论分割方法等重要混杂因素及模拟剂量学评估所需的特定血管造影考量,并首次引入「剂量学血管造影」概念。

主要发现

  • 报告的主要结果为阈值肿瘤剂量:90Y树脂微球100–120 Gy、90Y玻璃微球205–257 Gy可获缓解。
  • 报告了MAA剂量学及MAA PVT靶向对总生存的影响。
  • 玻璃微球治疗良好PVT候选者(肿瘤吸收剂量≥205 Gy且PVT靶向良好)中位总生存20.2个月,差候选者(肿瘤吸收剂量<205 Gy或PVT靶向差)仅3个月。
  • 同一研究中12%患者降期后切除。

关键数值与推荐

  • 90Y树脂微球获缓解的肿瘤剂量阈值为100–120 Gy。
  • 90Y玻璃微球获缓解的肿瘤剂量阈值为205–257 Gy。
  • 良好PVT候选者定义为肿瘤吸收剂量≥205 Gy且PVT靶向良好。
  • 差PVT候选者定义为肿瘤吸收剂量<205 Gy或PVT靶向差。

临床怎么用

  • 对伴PVT的HCC患者行90Y微球SIRT前,可采用99mTc-MAA SPECT/CT预测剂量学进行个体化剂量评估。
  • 根据树脂或玻璃微球对应的肿瘤剂量阈值及PVT靶向情况筛选良好候选者以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioembolization with 90Y-loaded microspheres based on classical prescription methods is increasingly applied to hepatocellular carcinoma (HCC) patients with portal vein thrombosis (PVT). In recent years, pretherapeutic predictive dosimetry based on technetium-99m macroaggregated albumin (MAA) quantitative scintigraphy using SPECT/CT has been developed. This paper presents an overview on the MAA-based dosimetry concept, discusses important confounding factors, such segmentation methods, and specific angiographic considerations required for a simulation-based dosimetric evaluation. The concept of "dosimetric angiography" is then introduced for the first time. Main results available are reported as a threshold tumor dose, allowing a response, between 100 and 120 Gy with 90Y-loaded resin microspheres and between 205 and 257 Gy with 90Y-loaded glass microspheres. Impact of MAA-based dosimetry and MAA PVT targeting on overall survival is also reported. Due to those dosimetric advances, personalized dosimetric approaches based on MAA dosimetry are now available, with specific endpoints, for both 90Y-loaded resin or glass microsphere. The clinical impact of personalized dosimetry in PVT patients is particularly high, as a median overall survival of 20.2 months has been reported for good PVT candidate treated with glass microspheres (tumor-absorbed dose ≥205 Gy and good PVT targeting) as against only 3 months for poor candidate (tumor-absorbed dose <205 Gy or poor PVT targeting), and as a significant amount of patients where downstaged and resected (12%) in the same study.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Garin E, Rolland Y, Edeline J, et al. 90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry. Semin Nucl Med. 2019. PMID: 30954188. doi:10.1053/j.semnuclmed.2019.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。